The historical rank and industry rank for Matinas BioPharma Holdings's Pretax Margin % or its related term are showing as below:
MTNB's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.63 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Matinas BioPharma Holdings Pretax Margin % Related Terms
Matinas BioPharma Holdings Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MTNB vs DRMA, MBIO, ADIL: Pretax Margin % Comparison
For the Biotechnology subindustry, Matinas BioPharma Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Matinas BioPharma Holdings Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Matinas BioPharma Holdings's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Matinas BioPharma Holdings (MTNB) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Matinas BioPharma Holdings and its competitors. According to the industry distribution chart, Matinas BioPharma Holdings ranks #999999 out of 945 companies in the Biotechnology industry.
Is Matinas BioPharma Holdings' Pretax Margin % too high?
Matinas BioPharma Holdings' current Pretax Margin % is %. Based on the distribution chart, Matinas BioPharma Holdings ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Matinas BioPharma Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Matinas BioPharma Holdings' Pretax Margin % compare to DRMA and MBIO?
According to the Biotechnology industry distribution chart, Matinas BioPharma Holdings ranks #999999 out of 945 companies for Pretax Margin %. This places Matinas BioPharma Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Matinas BioPharma Holdings and its competitors. Matinas BioPharma Holdings's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Matinas BioPharma Holdings stock overvalued right now?
Matinas BioPharma Holdings (MTNB) has a current Pretax Margin % of %. The current Pretax Margin % is %. Matinas BioPharma Holdings' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Matinas BioPharma Holdings (MTNB), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
30GF Score
Get the complete analysis for MTNB
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MTNB has been successfully added to your 
